Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Drug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Fineline Cube Jul 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...

Medical Device Policy / Regulatory

NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China

Fineline Cube Jul 25, 2023

The National Medical Products Administration (NMPA) has released an updated version of the “List of...

Policy / Regulatory

Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023

Fineline Cube Jul 25, 2023

The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...

Policy / Regulatory

NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update

Fineline Cube Jul 24, 2023

The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive...

Company Deals

Carbon Medical Technology Secures Over RMB 100 Million in Series A Financing for Interventional Therapy

Fineline Cube Jul 24, 2023

Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9...

Company Drug

BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment

Fineline Cube Jul 24, 2023

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...

Company Drug

CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032

Fineline Cube Jul 24, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...

Company Deals Drug

Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program

Fineline Cube Jul 24, 2023

Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...

Legal / IP Policy / Regulatory

National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector

Fineline Cube Jul 24, 2023

The emergency response department of the National Health Commission (NHC) has released a notification signaling...

Company

FDA Assures No Disruption to US Drug Supply Chain After Pfizer Warehouse Tornado

Fineline Cube Jul 24, 2023

The US Food and Drug Administration (FDA) has issued a statement this week, ruling out...

Company Deals

Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies

Fineline Cube Jul 21, 2023

China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...

Company Drug

Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment

Fineline Cube Jul 21, 2023

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...

Company Deals

Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program

Fineline Cube Jul 21, 2023

US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva...

Company Deals

Acotec Scientific and Boston Scientific Announce Comprehensive Collaboration Agreement

Fineline Cube Jul 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a cooperation framework and service framework...

Company Drug

Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment

Fineline Cube Jul 21, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...

Company Drug

GenScript Biotech’s CAR-T Therapy Carvykti Reports USD 117 Million in Sales

Fineline Cube Jul 21, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company

SCG Cell Therapy Launches Global Manufacturing and R&D Center in Singapore with Automated System

Fineline Cube Jul 21, 2023

Singapore-based SCG Cell Therapy Pte. Ltd has announced the initiation of its global manufacturing and...

Company Deals

Zennova Pharmaceutical Group Secures RMB 100 Million in Series B Financing for Commercial Manufacturing and R&D

Fineline Cube Jul 21, 2023

China-based Zennova Pharmaceutical Group has reportedly raised close to RMB 100 million (USD 13.9 million)...

Company Drug

Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review

Fineline Cube Jul 21, 2023

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation...

Company Legal / IP

Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent

Fineline Cube Jul 21, 2023

The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and...

Posts pagination

1 … 476 477 478 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.